Nvidia Options Price in $280 Billion Earnings Swing 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Trump Buys SpaceX Shares After Record IPO 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Add as a preferred source on Google
CAMBRIDGE, Mass., April 23, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, will report first quarter 2018 financial results after the Nasdaq Global Market closes on Thursday, May 3, 2018. Subsequently, at 4:30 p.m. Eastern Time, the Company will host a conference call to discuss its first quarter 2018 financial results and to provide a corporate update.
The conference call may be accessed by dialing 844-534-7313 for domestic callers and +1-574-990-1451 for international callers. The passcode for the call is 2798939. Please specify to the operator that you would like to join the "Sarepta First Quarter 2018 Earnings Call". The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
